

# Circular RNA hsa\_circ\_0023404 promotes the proliferation, migration and invasion in endometrial cancer cells through regulating miR-217/MAPK1 axis

**Zhuoying Chen**

Fujian Medical Universtiy affiliated Mindong Hospital

**Meixiu Huang**

Fujian Medical Universtiy affiliated Mindong Hospital

**Jiaying You**

Fujian Medical Universtiy affiliated Mindong Hospital

**Yanhua Lin**

Fujian Medical Universtiy affiliated Mindong Hospital

**Qiaoyun Huang** (✉ [mdyyczy789@163.com](mailto:mdyyczy789@163.com))

Fujian Medical Universtiy affiliated Mindong Hospital

**Caiping He**

Fujian Medical Universtiy affiliated Mindong Hospital

---

## Research Article

**Keywords:** hsa\_circ\_0023404, miR-217, MARK1, Circular RNA, endometrial cancer

**Posted Date:** February 10th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1310140/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Aim:** Studies indicated that Circular RNA hsa\_circ\_0023404 play a critical role in cancer progression. The aim of our research is to investigate the functions of hsa\_circ\_0023404 in endometrial cancer [EC] and the potential molecular mechanism.

**Methods:** We used RT-qPCR and Western blot approach to detect the expressed levels of related genes in EC cell lines. Transfected siRNAs were applied to knockdown the level of related mRNA in cells. Cell proliferation by CCK-8 assay and colony formation assay were applied to detect cell proliferation. Transwell migration and invasion assay was for detecting the migration and invasion of the cells.

**Results:** RT-qPCR showed that the level of hsa\_circ\_0023404 and MARK1 mRNA were upregulated but miR-217 was decreased in three endometrial cancer cell lines. Knockdown of hsa\_circ\_0023404 by siRNA markedly increased the level of miR-217 and reduced the proliferation of the Ishikawa cells. It also inhibited the cell migration and invasion. Anti-miR-217 can reverse the promoted proliferation, migrations and invasion of Ishikawa cells mediated by si-circ\_0023404. si-MARK1 restored the inhibited cell proliferation, migration and invasion of the co-transfected Ishikawa cells with si- circ\_0023404 and anti-miR-217.

**Conclusion:** hsa\_circ\_0023404 exerts a tumor-promoting role in endometrial cancer by regulating miR-217/MARK1 axis. hsa\_circ\_0023404 inhibit miR-217 as sponge which inhibit endometrial cancer cell growth and metastasis. MARK1 is downstream target of miR217 and upregulated by hsa\_circ\_0023404/miR-217 axis and involved in the endometrial cancer progression.

## Introduction

Endometrial cancer (EC) is one of the most common types of gynecological cancer and the fourth most common cancer among women. Morbidity and mortality rates among patients with EC remain high globally[1]. Each year, approximately 140,000 women worldwide develop endometrial cancer and an estimated 40,000 women die of this cancer. Most cases of EC are diagnosed after menopause and the highest incidence rate is around 70 years old. Survival is usually determined by the stage and histology of the disease, and the prognosis of endometrial cancer varies greatly in different stages and histological types. The most common lesions (type I) are typically hormone-sensitive and in low-stage with good prognosis, while type II tumors have a high grade and are prone to relapse even in the early stages[2].

Studies have shown that a large number of non-coding RNAs (such as microRNAs and long non-coding RNAs) are associated with the occurrence of gynecological diseases[3, 4]. Circular RNAs (circRNAs) belongs to a new class of non-coding RNAs and are formed by a peculiar pre-mRNA with a covalently closed continuous loop. Due to its structures, circRNA are resistant to degradation by exonuclease activity and more stable than linear RNAs. circRNAs have been implicated in microRNA (miRNA) sequestration, modulation of protein-protein interactions and regulation of mRNA transcription. Among them, the most striking function is acting as a miRNA sponge and regulate the expression of their downstream genes[5,

6]. CircRNAs were implicated not only involved in cellular physiological functions but also in various human pathologies including cancer. It was founded that circRNAs are aberrantly modulated in human cancer tissues. Furthermore, research is currently focusing on understanding the possible implications of circRNAs in diagnostics, prognosis prediction, and eventually therapeutic intervention in human cancer[3].

CircRNA hsa\_circ\_0023404 (chr11: 71668272-71671937) is derived from mRNA of ring finger protein 121 (RNF121, NM\_018320). Studies indicated that hsa\_circ\_0023404 play a critical role in cancer progression. For example, it showed that hsa\_circ\_0023404 can promote the proliferation, migration and invasion of non-small cell lung cancer (NSCLC cells) by regulating miR-217/ZEB1 axis[7]. Studies demonstrated that hsa\_circ\_0023404 was involved in cervical cancer by regulating miR-5047 and miR-136/TFCP2 /YAP pathway[8]. MicroRNAs (miRNAs or miRs) are a class of noncoding RNA molecules that negatively regulate the translation of messenger (m) RNAs by interacting with complementary sites in the 3' untranslated region (UTR)[9]. Many miRNAs act as tumor regulator genes by directly targeting oncogenes or tumor suppressor genes[10]. Recently, mounting evidence indicates that miR-217 can regulated tumor biology depending on the cell type [11, 12]. mitogen-activated protein kinase (MAPK) 1 is identified as a novel miR-217 target and the MAPK signaling is important in regulating pathological cell growth including cancer[13, 14].

These indicated that hsa\_circ\_0023404 and its target miR-217/MARK1 axis plays a critical role in cancer biology but the role of hsa\_circ\_0023404/miR-217/MARK1 involved in endometrial cancer was not investigated yet. In this study, we investigated the role of hsa\_circ\_0023404 promotes in endometrial cancer cells associated with miR-217/MAPK1 axis.

## Methods

### Cell culture

Human endometrial endothelial cell (HEEC) and human endometrial cancer cells (Ishikawa, RL95-2 and KLE) were purchased from the American Type Culture Collection (ATCC, USA) or National Infrastructure of Cell Line Resource (Beijing, China). Cells were incubated in DMEM (Gibco, USA) contained 10% fetal bovine serum (FBS; PAN biotech, Germany) and 1% penicillin/ streptomycin (Solarbio, China) at 37°C and 5% CO<sub>2</sub>.

### RT-qPCR

Total RNA was extracted using Neurozol reagent (MACHEREY-NAGEL, Germany) and cDNA was generated using reverse transcription reagent kit (PROMEGA, USA). Real time PCR was performed using SYBR Green PCR kit (TaKara, China). U6 and GAPDH are internal controls. The qPCR analysis was then performed on an ABI 7500 Real-time PCR System (Applied Biosystems, Thermo Fisher Scientific, USA) according to the instructions supplied by the manufacturer. The relative expression levels of the genes were calculated by comparing to U6 or GAPDH using  $2^{-\Delta\Delta CT}$  method. The primers were used as follows:

miR-217 FORWARD: CGCGTACTGCATCAGGAACTG;

miR-217 REVERSE: AGTGCAGGGTCCGAGGTATT;

miR-217-5p RT (anti-miR-217) Primer:

GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCAAT; U6 FORWARD:  
CTCGCTTCGGCAGCACA;

U6 REVERSE: AACGCTTCACGAATTTGCGT;

circ\_0023404 FORWARD: ACCGTGGCCATGAAGCTATG;

circ\_0023404 REVERSE: GGTCACCATATTGTAGGAGCGT;

GAPDH FORWARD: AGAAGGCTGGGGCTCATTTG;

GAPDH REVERSE: AGGGGCCATCCACAGTCTTC;

MAPK1 FORWARD: CAGTTCTTGACCCCTGGTCC;

MAPK1 REVERSE: GTACATACTGCCGCAGGTCA.

### **Cell transfection**

si-NC (negative control) sequence: UUCUCCGAACGUGUCACGUTT, si-circRNA (si-hsa\_circ\_0023404 #1-3; #3 sequence: GGUUCCUGCUAAUCUAUAATT, miR-217 or anti-miR-217 were synthesized by GenePharma(Shanghai, China). They were transfected in Ishikawa cells using Lipofectamine 3000 Reagent (Life Technologies, USA) and then culture in at 37°C and 5% CO<sub>2</sub> for 48-72 hrs.

### **Detection of cell proliferation by CCK-8 assay**

Ishikawa cells were plated at 2×10<sup>3</sup> cells/well in 96-well plates and grown in medium containing 10% FBS for 24 hrs. After transfection with siRNA, 10 µl of cell count kit-8 (CCK-8, CK04, Dojindo, Japan) was added into each well and cells were incubated for 2 hrs in a 5% CO<sub>2</sub> incubator at 37°C. The absorbance of each well at 450 nm was read in GloMax™ 96 MICROPLATE (Promega, USA).

### **Colony formation assay**

Ishikawa cells were transfected with siRNA for 48 hrs and trypsinized and dispensed into 6-well plates with a density of 800 cells/well. When the number of cells in a colony is more than 50, 10% formaldehyde was employed to fix colonies for 10 min and 0.5% crystal violet was adopted to stain colonies for 5 min. Images were photographed and the number of colonies was calculated by ImageJ.

### **Transwell migration and invasion assay**

For migration assay, transfected Ishikawa cells ( $1 \times 10^5$  cells) were suspended in 200ul serum-free medium and then seeded on the top chamber. Medium contained 10% FBS was added into the lower chamber. After 24 hrs of incubation, cells on the lower surface of the lower chamber were fixed with 4% PFA and stained with 0.1% crystal. Cell were counted from five randomly selected microscopic fields. For invasion assay, Transwell inserts (Fisher Scientific, USA) were coated with Matrigel (BD, USA). After 24 hrs incubation, cells on the upper surface of the Transwell membrane were gently removed, and cells on the lower surface of the Transwell membrane were fixed and stained with crystal violet, counted from five randomly selected microscopic fields.

## Western blotting

Cells were collected and lysed with RIPA buffer (Beyotime, China). Equal amount of protein was separated on SDS-PAGE and transferred to PVDF (Millipore, USA). Then, the membranes were incubated with the primary antibodies anti-MARK1 (Cat:125403, Novopro, China) and anti-actin (Sigma, USA). ECL substrates were used to visualize protein bands (Millipore, USA).

## Statistical analysis

All experiments were replicated thrice and all data was expressed as mean  $\pm$  standard deviation (SD). The software GraphPad 8.0 were used to carry out all statistical analyzes. Student's t-test and one-way ANOVA followed by Bonferroni 's post hoc test were utilized to analyze 2 or multiple groups, respectively. \* means  $p < 0.05$ ; \*\* means  $p < 0.01$ ; \*\*\* means  $p < 0.001$ .

# Results

## 1. Hsa\_circ\_0023404, miR-217 and MARK1 mRNA expression in endometrial cancer cell lines.

To examine the role of hsa\_circ\_0023404 and its target miR-217/MARK1 axis in endometrial cancer cell lines, The RT-qPCR was applied to determine the level of hsa\_circ\_0023404, miR-217 and MARK1 mRNA in human endometrial endothelial cell (HEEC) and three human endometrial cancer cells (RL95-2, KLE and Ishikawa). RT-qPCR showed that hsa\_circ\_0023404 (Fig. 1A) and MARK1 (Fig. 1C) were upregulated in RL95-2, KLE and Ishikawa cell lines compared to HEEC. On the contrary, miR-217 (Fig. 1B) was downregulated in RL95-2, KLE and Ishikawa cell lines compared to HEEC. Among the three cell lines, the results in Ishikawa cell were most strikingly and we employed the Ishikawa cells in further study.

## 2. Knockdown of hsa\_circ\_0023404 induces miR-217 and inhibits cell proliferation, migration and invasion in endometrial cancer cells

Since the level of hsa\_circ\_0023404 is upregulated in endometrial cancer cells, we investigate its biological role in endometrial cancer by knockdown of hsa\_circ\_0023404 with si-circ\_0023404 in Ishikawa cells. We first investigated the effect of siRNA targeted to hsa\_circ\_0023404 in the Ishikawa cell lines and it showed all three siRNAs significantly reduced mRNA expression of the hsa\_circ\_0023404 compared to control siRNA (si-NC) analyzed by RT-qPCR (Fig. 1D). Among the three circs\_0023404

siRNA, the siRNA#3 had the highest efficiency and was employed for subsequent experiments. We next examined the effect of si-circ\_0023404 on miR-217 in Ishikawa cells and it showed the si-circ\_0023404#3 reduced the level of circ\_0023404 (Fig. 1E) while the level of miR-217 was up-regulated (Fig. 1F). These were consistent with that the circ\_0023404 inhibited the miR-217 expression acting as a miRNA sponge. We determined cell proliferation by CCK-8 assay in siRNA treated Ishikawa cells and it showed that downregulation of hsa\_circ\_0023404 markedly decreased the proliferation of the Ishikawa cells detected by CCK-8 assay (Fig. 1G). down-regulation of hsa\_circ\_0023404 also markedly decreased the capacity of colony formation of in Ishikawa cells compared to control (Fig. 1H, I). These data indicated that hsa\_circ\_0023404 promoted the proliferation of endometrial cancer cells. Consistently, knockdown of hsa\_circ\_0023404 inhibited the cell migration in Ishikawa cells analyzed by Transwell migrations assay (Fig. 1J, K). Inhibition on cell invasion after hsa\_circ\_0023404 knockdown was also observed in Transwell invasion assay (Fig. 1J, L). These data indicated that hsa\_circ\_0023404 promoted cell proliferation, migration and invasion in endometrial cancer cells.

### **3. miR-217 inhibits cell proliferation, migration and invasion in endometrial cancer cells**

To investigate the role of miR-217 in endometrial cancer cells, Ishikawa cells were transfected with mimic NC and miR-217 mimic. The expression of transfected miR-217 mimic was confirmed by RT-qPCR (Fig. 2A). CCK-8 assay demonstrated that miR-217 mimic markedly decreased the proliferation of the Ishikawa cells (Fig. 2B). miR-217 mimic also markedly decreased the capacity of colony formation of in Ishikawa cells compared to mimic NC (Fig. 2C, D). In parallel, it showed that miR-217 reduced the cell migration in Ishikawa cells analyzed by Transwell migrations assay (Fig. 2E, F). Inhibition on cell invasion after miR-217 mimic transfection was also observed in Transwell invasion assay (Fig. 2E, G). MARK1 is the target of miR-217 and WB analysis confirmed that the miR-217 mimic transfection decreased the expression of MARK1 protein in Ishikawa cells (Fig. 2H, I). These data indicated that miR-217 play a critical role in inhibiting cell proliferation, migration and invasion in endometrial cancer cells and MARK1 protein is one downstream target of miR-217.

### **4. Hsa\_circ\_0023404 promotes the proliferation, migration and invasion in endometrial cancer cells by sponging miR-217**

Studies indicated that miR-217 was one sponge target of hsa\_circ\_0023404 and we examined their interaction by co-transfection with si-circ\_0023404 and anti-miR-217 (miR-217 inhibitor). co-transfection showed that si-circ\_0023404 attenuated the expression level of hsa\_circ\_0023404 while anti-miR-217 increased hsa\_circ\_0023404 (Fig. 3A); si-circ\_0023404 increased the expression level of miR-217 while anti-miR-217 blocked the increased miR-217 (Fig 3B). CCK-8 assay showed that downregulation of hsa\_circ\_0023404 decreased the proliferation of the Ishikawa cells but anti-miR-217 reversed the decrease (Fig. 3C, D). Transwell migrations and invasion assay (Fig. 2E, F) also indicated that anti-miR-217 blocked the promoted migrations and invasion of Ishikawa cells mediated by si-circ\_0023404.

Summary, these data showed that anti-miR-217 can block the promoted proliferation, migrations and invasion of Ishikawa cells by si-circ\_0023404, indicating that the promoted proliferation, migrations and

invasion by circ\_0023404 is dependent on miR-217 and consistent with that hsa\_circ\_0023404 act as sponge of miR-217.

## 5. MARK1 is involved in hsa\_circ\_0023404/miR-217 mediated biological behavior of endometrial cancer

MARK1 is a potential target of miR-217 and our data showed that anti-miR-217 increased the MARK1 protein level which was blocked by co-transfection with si\_circ\_0023404 and anti-miR-217, supporting that MARK1 is downstream of the hsa\_circ\_0023404/miR217 axis(Fig. 4A). We further apply siRNA target to MARK1 to knockdown the expression of MARK1 and Western blot showed that si-MARK1 can downregulate the induced MARK1 by co-transfection with si\_circ\_0023404 and anti-miR-217. si-MARK1 restored the inhibited cell proliferation of the co-transfected Ishikawa cells with si- circ\_0023404 and anti-miR-217 analyzed by CCK8 assay (Fig.4E) and colony formation assay (Fig. 4F, G). In parallel, it showed that si-MARK1 restored the inhibition in migration (Fig. 5A) and invasion (Fig. 5B) of the co-transfected Ishikawa cells with si-circ\_0023404 and anti-miR-217 analyzed by Transwell migrations and invasion assay. These data indicated the MARK1 is downstream of hsa- circ\_0023404/miR-217 axis and MARK1 knockdown by si-MARK1 can block the promotion of cancer biology mediated by si-circ\_0023404/miR-217 axis. These data support that MARK1 is downstream of hsa\_circ\_0023404/miR-217 and plays a critical role in hsa\_circ\_0023404/miR-217 mediated endometrial cancer biology.

## Discussion

Plenty of studies indicated that circular RNA hsa\_circ\_0023404 is associated with tumorigenesis. In this study, we found that hsa\_circ\_0023404 was upregulated with decreased miR-217 in endometrial cancer cell lines. Knockdown of hsa\_circ\_0023404 lead to increased miR-217 and inhibited the proliferation and metastasis of endometrial cancer cells. Anti-miR-217 can reverse the inhibition by si-circ\_0023404. These data indicated that hsa\_circ\_0023404 promoted the proliferation, migration and invasion in endometrial cancer cells by sponging miR-217. In further study, knockdown of MARK1 blocked the promotion of cancer biology mediated by si-circ\_0023404/miR-217 axis, supporting that MARK1 is the target of miR-217 and involved in circ\_0023404/miR-217 mediated endometrial cancer biology.

In human cancer, circRNAs were implicated in the control of oncogenic

activities such as tumor cell proliferation, epithelial-mesenchymal transition, invasion, metastasis and chemoresistance. The most widely described mechanism of action of circRNAs is their ability to act as competing endogenous RNAs (ceRNAs) for miRNAs, lncRNAs and mRNAs, thus impacting along their axis [2, 15, 16]. Several studies revealed that circRNA hsa\_circ\_0023404 play critical role in tumorigenesis. For example, it enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047[8]. hsa\_circ\_0023404 is also involved in cervical cancer progression through /miR-136/ TFCEP2/YAP axis. hsa\_circ\_0023404 promoted TFCEP2 expression via inhibiting miR-136, leading to activation of YAP signaling pathway[17]. hsa\_circ\_0023404 was shown to interact with miR-217/ZEB1 axis to contribute to the growth, migration and invasion of NSCLC cells[7].

Dysregulated miRNA expression was involved in malignancies and miRNAs may serve as tumor suppressor or oncogene to participate in human cancer progression. As a miRNA, miR-217 is closely linked to tumor progression and poor prognosis[18, 19]. Previous studies have reported that miR-217 bound to its target mRNA to inhibit the formation and progression of tumors, including gastric cancer [19]. Bioinformatics identified MARK1 protein is the target of miR-217 in cancer cells. There are two binding sequences for miR-217 in MAPK1 3'UTRs which was confirmed by the luciferase activity assay[20]. The MAPK pathway is effectively involved in the regulation of cancer cell proliferation, invasion and survival and considered as a potential target for cancer therapeutic intervention. Previous studies have confirmed that increased MAPK1 expression could function as tumor promoter in human hepatocellular carcinoma (HCC) [21, 22], ovarian cancer[23] and cervical cancer[24]. Consistently, previous study showed that downregulated MAPK1 by miR-217 facilitated the metastasis and EMT process of HCC cells, indicating that miR-217 suppressed HCC via negatively modulating MAPK1 expression[25]. It also is reported that circMAN2B2 acted as an onco-miRNA in HCC by sponging miR-217 to promote MAPK1 expression[26]. Our data provided the evidence that MARK1 is the downstream target of miR-217 and hsa\_circ\_0023404 promoted the proliferation, migration and invasion in endometrial cancer cells through regulating miR-217/MARK1 axis.

With the advancement of RNA sequencing technology and the rapid development of bioinformatics, a large number of circRNAs were discovered widely involved in a variety of cancer-related pathogenesis, drug resistance and played an important role in the diagnostic and prognostic biomarker and the therapeutic target in human cancer [27]. The powerful functions and unique properties of circRNAs have made them the focus of scientific and clinical research. CircRNAs can be detectable in body fluids, such as blood and urine, including membrane-bound vesicles, such as exosome. The exosomal circRNAs could discriminate cancer patients from healthy individuals, identifying new potential exosome-based cancer biomarkers[28, 29]. The unique cellular stability and capacity of circRNA to sponge miRNA and protein may place circRNA as a promising vehicle for the delivery of cancer therapeutics[30].

## Conclusion

In this study, our data demonstrated that hsa\_circ\_0023404 exerts a tumor-promoting role in endometrial cancer by regulating miR-217/MARK1 axis. The hsa\_circ\_0023404 act as sponge for and inhibit miR-217 which inhibit endometrial cancer cell growth and metastasis. MARK1 is downstream target of miR217 and the induced MARK1 by hsa\_circ\_0023404 through miR217 inhibition contribute to the endometrial cancer progression. Targeting or knockdown of hsa\_circ\_0023404 by short hairpin RNA (shRNA) or CRISPR technique would be a potential therapeutic approach for endometrial cancer and will be investigated in the future.

## Declarations

## Acknowledgements

Not applicable.

## Author contributions

Zhuoying Chen, Qiaoyun Huang and Caiping He designed the study; Zhuoying Chen, Meixiu Huang, Jiaying You and Yanhua Lin performed experiments, collected and analysed data; Zhuoying Chen, Qiaoyun Huang and Caiping He wrote the manuscript. All authors read and approved the final manuscript.

## Funding

This study was funded by Natural Science Foundation of Fujian Province (Grant No. 2020J011335)

## Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics Approval** Not applicable

**Consent to participate** Not applicable

**Consent for Publication** Not applicable.

**Conflict of Interest** The authors declare no competing interests.


## References

1. Braun, M.M., E.A. Overbeek-Wager, and R.J. Grumbo, *Diagnosis and Management of Endometrial Cancer*. Am Fam Physician, 2016. **93**(6): p. 468-74.
2. Guo, J., J. Tong, and J. Zheng, *Circular RNAs: A Promising Biomarker for Endometrial Cancer*. Cancer Manag Res, 2021. **13**: p. 1651-1665.
3. Fontemaggi, G., et al., *New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer*. Cancers (Basel), 2021. **13**(13).
4. Anastasiadou, E., L.S. Jacob, and F.J. Slack, *Non-coding RNA networks in cancer*. Nat Rev Cancer, 2018. **18**(1): p. 5-18.
5. Nisar, S., et al., *Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies*. Front Cell Dev Biol, 2021. **9**: p. 617281.
6. Tang, X., et al., *Review on circular RNAs and new insights into their roles in cancer*. Comput Struct Biotechnol J, 2021. **19**: p. 910-928.
7. Liu, C., Z. Zhang, and D. Qi, *Circular RNA hsa\_circ\_0023404 promotes proliferation, migration and invasion in non-small cell lung cancer by regulating miR-217/ZEB1 axis*. Onco Targets Ther, 2019.

- 12:** p. 6181-6189.
8. Guo, J., et al., *Hsa\_circ\_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047*. Biomed Pharmacother, 2019. **115:** p. 108957.
  9. Kalla, R., et al., *MicroRNAs: new players in IBD*. Gut, 2015. **64(3):** p. 504-17.
  10. Kong, Y.W., et al., *microRNAs in cancer management*. Lancet Oncol, 2012. **13(6):** p. e249-58.
  11. Menghini, R., et al., *MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1*. Circulation, 2009. **120(15):** p. 1524-32.
  12. Xia, H., L.L. Ooi, and K.M. Hui, *MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer*. Hepatology, 2013. **58(2):** p. 629-41.
  13. Giehl, K., et al., *Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration*. Oncogene, 2000. **19(25):** p. 2930-42.
  14. Zhang, N., C. Lu, and L. Chen, *miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer*. Oncol Lett, 2016. **12(6):** p. 4589-4597.
  15. Vo, J.N., et al., *The Landscape of Circular RNA in Cancer*. Cell, 2019. **176(4):** p. 869-881 e13.
  16. Tran, A.M., et al., *A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs*. Front Cell Dev Biol, 2020. **8:** p. 50.
  17. Zhang, J., et al., *Circular RNA hsa\_circ\_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway*. Biochem Biophys Res Commun, 2018. **501(2):** p. 428-433.
  18. Tian, Y.W., et al., *Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma*. Minerva Med, 2017. **108(2):** p. 108-113.
  19. Zhang, Q., et al., *MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACH1*. J Cancer, 2015. **6(2):** p. 184-91.
  20. Zhu, L., S. Yang, and J. Wang, *miR-217 inhibits the migration and invasion of HeLa cells through modulating MAPK1*. Int J Mol Med, 2019. **44(5):** p. 1824-1832.
  21. Guegan, J.P., et al., *MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells*. Carcinogenesis, 2013. **34(1):** p. 38-47.
  22. Lin, L., et al., *CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression*. Cell Death Dis, 2014. **5:** p. e1488.
  23. Yiwei, T., et al., *HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion*. Med Sci Monit, 2015. **21:** p. 1856-63.
  24. Li, X.W., M. Tuergan, and G. Abulizi, *Expression of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis*. Asian Pac J Trop Med, 2015. **8(11):** p. 937-943.


25. Wang, H., et al., *Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis*. J Cell Mol Med, 2018. **22**(12): p. 5862-5876.
26. Wang, L.P., J.P. Wang, and X.P. Wang, *HOTAIR contributes to the growth of liver cancer via targeting miR-217*. Oncol Lett, 2018. **15**(5): p. 7963-7972.
27. Tang, Q. and S.S. Hann, *Biological Roles and Mechanisms of Circular RNA in Human Cancers*. Onco Targets Ther, 2020. **13**: p. 2067-2092.
28. Wang, S., et al., *Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies*. Mol Cancer, 2021. **20**(1): p. 13.
29. Chen, Q., et al., *Exosomal Non-coding RNAs-Mediated Crosstalk in the Tumor Microenvironment*. Front Cell Dev Biol, 2021. **9**: p. 646864.
30. He, A.T., et al., *Targeting circular RNAs as a therapeutic approach: current strategies and challenges*. Signal Transduct Target Ther, 2021. **6**(1): p. 185.

## Figures




**Figure 1**

**The role of hsa\_circ\_0023404 knockdown in endometrial cancer cells.** The total RNA of HECC and Ishikawa [RL95-2] KLE endometrial cancer cell lines were collected and subjected to RT-qPCR. RT-qPCR analysis shows the level of hsa\_circ\_0023404 (A) miR-217 (B) and MARK1 mRNA (C) in HECC and Ishikawa [RL95-2] KLE endometrial cancer cell lines respectively. Ishikawa cell was transfected with control si-NC and si-circ\_0023404 #1-3 for 48 hrs and subjected to RT-qPCR analysis. The level of hsa\_circ\_0023404 was knockdown by si-circ\_0023404 (si-circ) #1-3 in Ishikawa cell analyzed by RT-qPCR (D). The level of hsa\_circ\_0023404 (E) and miR-217 (F) was analyzed by RT-qPCR after si-circ #3 transfection. Cell proliferation was evaluated by CCK-8 assay (G) and colony formation assay (H, I) in si-NC or si-circ\_0023404 transfected Ishikawa cells. The migration and invasion capacity of Ishikawa cell cells was determined by Transwell migration and invasion assay after transfected with si-NC or si-circ\_0023404 (J). The statistics of Transwell migration (K) and invasion (L) assay for Ishikawa cells transfected with si-NC or si-circ\_0023404.




**Figure 2**

**miR-217 inhibits the proliferation of endometrial cancers through by miR-217/MARK1 axis.** Ishikawa cell was transfected with control mimic-NC and miR-217 mimic for 48 hrs and subjected to RT-qPCR analysis to examine the presence of miR-217 (A). Cell proliferation was evaluated by CCK-8 assay (B) and colony formation assay with statistics (C, D) after transfection. The migration and invasion capacity of Ishikawa cell cells was determined by Transwell migration and invasion assay after transfection(E). The statistics of Transwell migration (F) and invasion (G) assay were analyzed. Western blot was applied to examine the level of MARK1 protein with an anti-MARK1 antibody (H) after transfection with mimic-NC and miR-217 mimic. The statistics of WB were analyzed (I).



**Figure 3**


**circ\_0023404 promotes the proliferation, migration and invasion of endometrial cancers by sponging miR-217.** Ishikawa cell was transfected with control si-NC and si-circ\_0023404 with anti-NC or anti-miR-217 for 48 hrs as labelling and subjected to: RT-qPCR analysis to examine the level of circ\_0023404 (A) and miR-217 (B). Cell proliferation was evaluated by CCK-8 assay (C) and colony formation assay with statistics (D, E) after co-transfection. The migration (F, top) and invasion (F, bottom) capacity of Ishikawa cell cells was determined by Transwell migration and invasion assay after co-transfection. The statistics of Transwell migration (G) and invasion (H) assay were analyzed.



**Figure 4**

**circ\_0023404 promotes the proliferation of endometrial cancers through by miR-217/MARK1 axis.**

Ishikawa cell was transfected with control si-NC or si-circ\_0023404 with anti-miR-217 for 48 hrs and subjected to WB to detect the level of MARK1 protein (A) and the statistics was analyzed (B). Ishikawa cell co-transfected with si-circ\_0023404, anti-miR-217 with si-MARK1 for 48 hrs and subjected to WB to detect the level of MARK1 protein (C) and the statistics was analyzed (D). Cell proliferation was evaluated by CCK-8 assay (E) and colony formation assay with statistics (F, G) after co-transfection.



**Figure 5**

**circ\_0023404 promotes migration and invasion of endometrial cancers through by miR-217/MARK1 axis.** Ishikawa cell co-transfected with si-circ\_0023404, anti-miR-217 with si-MARK1 for 48 hrs and subjected to Transwell migration and invasion assay (A). The statistics of Transwell migration (B) and invasion (C) assay were analyzed.